Loading clinical trials...
Loading clinical trials...
B-acute lymphoblastic leukaemia (ALL) is the most common childhood malignancy. Despite enhancement of childhood B-ALL outcome, relapses remain difficult to treat. Several studies in adult acute myeloid leukaemia have shown that proliferation of immunosuppressive cells -particularly T regulatory (Treg) cells and deficient natural killer (NK) cells- was associated with poor response to chemotherapy. However, few studies have been done on childhood ALL and none on relapse of B-ALL. Moreover, a newly described immunosuppressive B cells subset (Breg cells) seems to have a role in oncogenesis in mice model, but its significance has never been evaluated in human cancers. The purpose of this study is to prospectively evaluate the immune status of children newly diagnosed with first relapse of B-cell ALL, and to compare results with those of children treated for B-ALL in complete remission. Classic lymphocytic phenotype, proportions of immunosuppressive cells (Treg cells, deficient NK cells, Cytotoxic T-lymphocyte-associated protein 4 and/or Programmed T cell death 1) and thymopoiesis will be evaluated. The investigators assume that increase of immunosuppressive cells proportions could be associated with B-ALL relapse.
Age
1 - 18 years
Sex
ALL
Healthy Volunteers
No
University Hospital of Amiens
Amiens, France
University Hospital of Angers
Angers, France
University Hospital of Besancon
Besançon, France
University Hospital of Bordeaux
Bordeaux, France
University Hospital of Caen
Caen, France
Civil Hospices of Lyon
Lyon, France
University Hospital of Marseille
Marseille, France
University Hospital of Nancy
Nancy, France
University Hospital of Nantes
Nantes, France
University Hospital of Nice
Nice, France
Start Date
January 1, 2016
Primary Completion Date
September 1, 2022
Completion Date
September 1, 2022
Last Updated
October 3, 2022
119
ACTUAL participants
Collection of blood samples
BIOLOGICAL
Lead Sponsor
University Hospital, Angers
NCT05453500
NCT07224100
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions